Acute promyelocytic leukemia (APL) is characterized by typical morphological manifestation, t(15;17) translocation and active response to all-trans retinoic acid (ATRA) in the great majority of patients. However, a subset of APL cases may present atypical phenotypic, cytogenetic or molecular features at different stages of the disease. The biological and clinical significance of these features sometimes remains obscure. In this study, 284 APL patients were cytogenetically analyzed and precise diagnosis was performed according to the molecular cytogenetic results. Twenty-six APL patients were identified as having additional, complex and/or variant chromosomal abnormalities at diagnosis or at relapse, 16 of them being further analyzed using fluorescence in situ hybridization (FISH) or chromosome painting (CP). Interestingly, some of these chromosomal aberrations were found to be associated with atypical morphology and/or drug response, indicating a genotype-phenotype correlation. Analysis of the complex karyotype may also allow a better understanding of the levels of cellular origin of the leukemogenesis. Examination of the remission induction and survival data showed that the presence of the additional/complex chromosome abnormalities was related to the prognosis in both primarily diagnosed and relapsed patients in this series. Leukemia (2001) 15, 1359-1368.
Introduction
Acute promyelocytic leukemia (APL) is characterized by specific clinical, cytogenetic and molecular features. The reciprocal translocation t(15;17)(q22;q21) results in the fusion of the promyelocytic leukemia (PML) gene with the retinoic acid receptor (RAR␣) gene, which is found in the great majority of APL patients. 1 PML-RAR␣ fusion protein, an aberrant retinoic acid receptor with altered DNA and protein binding activity, is believed to play an important role in leukemogenesis, 2 as recently confirmed by transgenic mice models. 3 Up to now, APL patients with t(15;17) are regarded as a favorable group among acute leukemia, mainly because of its unique sensitivity to all-trans retinoic acid (ATRA), yielding complete remission (CR) rates of 80-90%. 4 Since 1992, the therapeutic effect of arsenic trioxide (As 2 O 3 ) for primarily diagnosed and relapsed APL patients has also been proven. 5 However, a subset of APL patients possess, in addition to t (15;17) , some other chromosome abnormalities either at diagnosis or at relapse, with the incidence ranging from 29% to 43% in previous reports. [6] [7] [8] A trisomy 8 was the most frequent secondary changes reported in many studies. [9] [10] [11] An isochromosome of derivative chromosome 17 and a deletion of 9 q were also frequently detected in APL patients with additional aberrations. t (15;17) concomitant with other specific translocations is rare, reflecting disease evolution and progression. [12] [13] [14] In rare cases, variant chromosome translocations have been reported, which fuse RAR␣ gene with partner genes other than PML, such as t(11;17)(q23;q21), 15 t(5;17)(q35;q21), 16 t(11;17)(q13;q21) 17 and dup(17)(q21.3q23). 18 Apart from the cytogenetic heterogeneity, molecular studies on APL patients also revealed heterogeneity of the PML-RAR␣ transcripts as a result of the variability of the chromosome 15 breakpoints. The breakpoints located within bcr1, bcr2 and bcr3 generate three PML-RAR␣ isoforms known as L-, V-and S-type transcripts. 6, 19, 20 Whether the cytogenetic and molecular heterogeneities have the relevance to clinical outcome in APL remains controversial.
In this study, we reviewed the karyotypes of the patients who were diagnosed as APL and cytogenetically examined in our institute from 1988 to 1999. Particular attention was paid to a series of patients with additional, complex and/or variant karyotypic abnormalities, some of them being further analyzed using fluorescence in situ hybridization (FISH) and chromosome painting (CP). The possible relationships of these karyotypic abnormalities to phenotypic variations and to clinical prognosis were investigated.
Materials and methods

Patients
From 1988 to 1999, most patients with clinical and cytological diagnosis of APL in different hospitals in Shanghai were enrolled in our study. Further analysis of these patients was carried out for detailed clinical evaluation, morphological criteria of the French-American-British (FAB) classification, cytogenetic studies and RT-PCR analysis for PML-RAR␣ and variant fusion gene transcripts. ATRA was given as major remission induction for primarily diagnosed cases, whereas chemotherapy and more recently As 2 O 3 were used as reinduction for relapsed patients. Hydroxyurea or moderate chemotherapy (daunorubicin 40 mg/m 2 /day × 3 days and Arac 100 mg/m 2 /day × 3 to 5 days) regimens were incorporated into ATRA or As 2 O 3 remission induction among patients with white blood cell counts (WBC) exceeding 10 × 10 9 /l. The protocols of chemotherapy, ATRA and/or As 2 O 3 as post-remission treatment were as previously reported. 5 
Statistical analysis
Analysis of relapse-free survival (RFS) and overall survival (OS) were estimated by Kaplan-Meier method. 21 Statistical analysis was performed with Cox proportional-hazards regression. All works were handled by STATA 5.0 package.
Leukemia
Morphological and cytochemical analysis FAB criteria was followed in morphological analysis. Cytochemical examination including peroxidase staining (POX), naphthol AS-D chloroacetate esterase (NAS-DCE), naphthol AS-D acetate esterase (NAS-DAE) and sodium fluoride (NaF) inhibition test were performed for diagnosis and classification.
Cytogenetic studies
Metaphase chromosomes were prepared from bone marrow (BM) cells after 24 h in vitro cultures without stimulation. RHG and/or GTG banding techniques were applied and karyotypic annotation was carried out according to the ISCN 22 (International System for Human Cytogenetic Nomenclature) guidelines.
Reverse transcription-PCR (RT-PCR) and sequencing
The methods of BM sample preparation, RNA extraction and RT-PCR protocols to detect PML-RAR␣ and PLZF-RAR␣ rearrangements were described in our previous report. 23, 24 NPM-RARa and RARa-NPM transcripts were examined on RT products driven by random primer. For NPM-RARa, a simple PCR was conducted with 5Ј primer (5Ј-atggaagattcgatggac-3Ј) and 3Ј primer (5Ј-acgcaccttctcaatgagc-3Ј). For RARa-NPM, a nested PCR system was used, RAR␣1 (5Ј-tgcctccctacgccttctt-3Ј) and NPM1 (5Ј-caagcaaagggtggagttcc-3Ј) primers for the first round and RAR␣2 (5Ј-tctccagcaccagcttccag-3Ј) and NPM2 (5Ј-tggaaccttgctaccacctcc-3Ј) for the second. In addition, wild-type RAR␣ and NPM were also PCR amplified as internal controls to check the effectiveness of the above primers. The PCR conditions for these two reciprocal fusion transcripts were similar to those for PML-RAR␣. 23 The RT-PCR products were sequenced using automatic sequencer (ABI 377, PE, Foster City, CA, USA).
FISH and CP
Dual-color FISH was performed using probes labeled by nick translation with either biotin or digoxigenin. Mapping details of probes used for FISH analysis, including those prepared in our own laboratory or provided by other research groups [25] [26] [27] [28] [29] or those purchased from Oncor (Gaithersburg, MD, USA) or Vysis (Downers Grove, IL, USA), were provided on Table 1. CP was carried out employing whole chromosome painting probes (WCP) for chromosomes 1, 2, 4, 5, 6, 8, 10, 11, 15, 16, 17, 18 and 22 (Cambio, Cambridge, UK; Oncor). All procedures were recommended by the manufacturer. Briefly, slides were air dried for at least 3 days before denaturation in 70% formamide/2 × SSC at 70°C and passed through an ethanol dehydration series. All probes were hybridized at 37°C overnight in a moist chamber. After washing, probes were detected using avidin conjugated Texas Red and FITC labeled antibodies. DAPI was used as counterstain. The images were captured on Cytovision (Applied Imaging, Sunderland, UK).
Results
Overall patient data
From 1988 to 1999, 1575 acute leukemia patients were cytologically and cytogenetically investigated in our institute. Among them, 1026 (65%) were classified as ANLL (acute nonlymphocytic leukemia or acute myeloid leukemia), and 549 (35%) as ALL (acute lymphocytic leukemia). Among the 1026 ANLL cases, there were 284 APL patients (262 newly diagnosed and 22 relapsed), accounting for 27.7% of the total. This higher percentage than those in general report (around 10-15%) could be explained by the successful use of ATRA/As 2 O 3 differentiation and apoptosis induction therapy in our institute, attracting APL patients from all over China.
Cytogenetic and molecular cytogenetic analysis
Several types of cytogenetic abnormality were found in this study: simple t(15;17), one single chromosomal anomaly in addition to t(15;17) (denoted as 'additional'), abnormality of more than one chromosome in addition to t(15;17) (denoted as 'complex'), and translocations involving chromosome 17q21 and a partner chromosome other than the chromosome 15q22 (denoted as 'variant'). Among 284 APL patients studied, 258 had simple t(15;17) by routine karyotyping. Two cases with variant translocations were identified, one having simple t(11;17)(q23;q21) and the other showing t(5;17) (q35;q21), with an additional del(12)(p13). Twenty-four (19 primarily diagnosed cases and five relapsed cases)/284 (8.5%) were proved to have chromosomal abnormalities apart from t(15;17), including 16 additional and eight complex karyotypes (Table 2) . Among the five patients (cases 3, 5, 8, 10, 24) relapsed with additional/complex chromosomal abnormalities, two had simple t(15;17) at first diagnosis, whereas cytogenetic data were not available at the disease presentation in three others.
Molecular cytogenetic study (FISH and/or CP) was performed in 16/26 patients ( Table 2 ). Some observations may be worth special mention. For example, very complex variant translocations were found in two patients ( Table 2 , cases 5 and 10). Case 5 had multiple structural alterations, t(5;15)(q14;q22), t(15;17)(q22;q21), and an insertion, ins (16;17)(p11p12;q?). Besides the reciprocal translocations between chromosome 15 and 17 further confirmed by RT-PCR and FISH (using Vysis and Oncor probes specific for PML and RAR␣) for both PML-RAR␣ and RAR␣-PML, the other PML gene was translocated to the chromosome 5 ( Figure 1A and 1AЈ), although no evidence was obtained if the second allele was disrupted by the translocation. Case 10 had a three-way translocation involving chromosomes 4, 15 and 17 at relapse. By combined use of dual-color CP, FISH (using PML-RAR␣-specific probes from Vysis) and RT-PCR, we found that RAR␣ was fused to PML on der (15) , with expression of PML-RAR␣ transcript, whereas no reciprocal RAR␣-PML fusion was observed at chromosome or mRNA level ( Figure 1 J-L). Concerning the additional chromosomal anomaly, chromosome 8 was the most frequently involved. Four patients (cases 1, 16, 19 and 21) had trisomy 8 and one case (10) had a duplication of 8q, as confirmed by triple or quadruple amplification of MYC gene on 8q using FISH ( Figure 1M ). In case 16, although only one cell presented trisomy 8 at diagnosis, most of the karyotypes showed the same aberration at relapse, indicating that the clone with trisomy 8 was prone to be expanded. Of note, in case 12 with chromosome 11q+, the additional part on chromosome 11 was confirmed as self duplication by CP, while FISH using MLL probe detected two pairs of signals on 11q ( Figure 1R ). Figure 1S showed the FISH result of case 23, which verified the fusion of NPM and RAR␣. In case 11, the ider(17)(q10)t(15;17)(q22;q21) co-existed with Ph chromosome ( Figure 1N ). In case 24, at relapse, the fusion signal of AML1-ETO was detected in most of the metaphases, while only normal signals were found for PML and RAR␣ on all metaphases examined. Finally, a case diagnosed as mixed AML-M2/M3 (26, Table 2 ) was also included into this series, in that the karyotype analysis revealed t(8;21) in five mitoses, and the simultaneous presence of t(8;21) and t (15;17) in two mitoses at diagnosis ( Figure 1T ).
RT-PCR results
RT-PCR results were available in 235 patients. L-type PML-RAR␣ transcript was detected in 177 patients, S-type found in 55 patients, while V-type in three patients, accounting for 75.3%, 23.4% and 1.3% of the total, respectively. Among patients with additional/complex karyotype, L-type was found in 17 and S-type in seven patients. In case 25, both PLZF-RAR␣ and RAR␣-PLZF were detected. However, in case 23, only NPM-RAR␣, but not the RAR␣-NPM fusion transcript, was detected. The result was reproducible with many independent experiments, while the PCR system was proven to be reliable by amplification of both wild-type RAR␣ and NPM using the same primer sets. BCR-ABL fusion transcript was positive in addition to PML-RAR␣ in case 11, while AML1-ETO was detected simultaneously with PML-RAR␣ in cases 24 and 26 (Table 2) .
Phenotypic variations and molecular cytogenetic heterogeneity
Morphological studies were performed by three cytological experts, independent of the cytogenetic examination. Then, the results were compared to those of karyotyping. Here, we present the detailed clinical and biological data of seven patients, including two with variant chromosomal translocation and five with both molecular cytogenetic heterogeneity and phenotypic ambiguity (also see Table 3 ).
Case 23 (the t(5;17) patient):
A 12-year-old boy was presented with the initial WBC count of 15.7 × 10 9 /l. Bone marrow aspirate showed a hypercellular marrow with 95% aberrant promyelocytes, most of them having heavy coarse azurophilic granulation in a quite abundant cytoplasm, with relatively regular nuclear outlines. No Auer rods were identified in the cytoplasm. Molecular study showed a NPM-RAR␣ transcript of 750 bp long. Sequencing of the products confirmed that the transcript was the S-type of NPM-RAR␣ isoform. However, the RAR␣-NPM transcript was not detected in this case. When the patient was enrolled in our hospital, he presented with severe DIC and died of cerebral hemorrhage after only 5 days of ATRA treatment (total dose of 240 mg).
Case 25 (the t(11;17) patient):
This was a 67-year-old male who had been reported in our previous paper.
15,24 DIC parameters was negative at diagnosis and the initial WBC was 4.1 × 10 9 /l. Bone marrow aspirate showed a hypercellular marrow with 69% promyelocytes. The leukemic cells showed regular nucleus, hypergranular cytoplasm, but without Auer rods. ATRA was given at a dose of 60 mg/day, and the treatment produced an early leukocytosis without obvious myeloid maturation. On day 20 of ATRA treatment, the patient died of pneumonia and respiratory failure. Molecular study showed presence of PLZF-RAR␣, RAR␣1-PLZF and RAR␣2-PLZF fusion transcripts. 15, 24 The chromosome 11 breakpoint was located in the intron 2 of PLZF gene.
Case 10:
At the time of diagnosis, the patient was cytolog- One fusion yellow signal was showed on der(5) and the split red signal was observed on der (17) .
ically diagnosed as a typical APL (Figure 1B-E) and achieved CR by ATRA. Upon relapse, the morphology and POX staining were changed to a status reminiscent of a microgranular APL, but the NaF inhibition test tended to support monocytic features. Meanwhile, there was an additional chromosome aberration of dup (8q). The re-induction with chemotherapy was ineffective.
Case 11:
Promyelocytes accounted for 31% of the cells in BM, characterized cytogenetically by the presence of both ider(17)(q10)t(15;17)(q22;q21) and Ph chromosome ( Figure  1N (adriamycin 40 mg/m 2 /day × 3 days; Ara-C 100 mg/m 2 /day × 7 days). However, the BM examination still showed 50% promyelocytes after 3 months of treatment, and the patient died.
Case 12:
At diagnosis, some BM cells showed monocytic traits, as confirmed by morphologic and cytochemical analysis ( Figure 1O-Q) . ATRA and chemotherapy were used to obtain CR. At relapse, the phenotype changed to typical APL. Dup (11q) existed consistently. When relapse occurred, the patient failed to respond to As 2 O 3 and died.
Case 24:
This patient had two cell populations at diagnosis, M3-type promyelocytes and aberrant myelocytes, accounting for 29% and 20% of the BM cells, respectively. Using RT-PCR, PML-RAR␣ was detected while AML1-ETO was negative. The patient was classified as having biphenotype of M3 and M2. The patient achieved CR by ATRA at primary diagnosis. Then the patient was consolidated with DA, AA protocols and VP-16 for four courses. After 10 months, the patient relapsed. At that time, there were high percentages of myeloblasts (51-64%) and aberrant myelocytes (14-19%), and t(8;21) became the only translocation revealed by cytogenetic examination. Although RT-PCR showed the presence of two fusion gene transcripts, AML1-ETO and PML-RAR␣, the FISH analysis revealed the AML1-ETO, but not the PML-RAR␣ fusion signal. Hence, the positive RT-PCR result for PML-RAR␣ could be derived from a minimal residual leukemic clone existing at the initial presentation of the disease. The patient failed to respond to As 2 O 3 and died.
Case 26: t(8;21) and t(15;17) were both detected in a subset of mitoses at diagnosis (Figure 1T ), although the dominant clone only contained t(8;21). The morphology tended to support the diagnosis of a mixed M2/M3 leukemia. Using chemotherapy, the patient achieved CR and remains in remission.
Prognostic studies Primarily diagnosed patients:
The long-term follow-up data after CR were available among 145 primarily diagnosed APL patients, including 15 with additional/complex karyotype (Nos 1, 2, 4, 7, 9, 12-20, 22) and 130 with sole t(15;17). There were no significant differences between the two groups in terms of WBCs (0. /l) in simple group) and age (9 to 74 (medium: 37) in additional/complex group vs 6 to 72 (medium: 35) in simple group). The 2-year RFS and OS of additional/complex group (40.00 ± 15.49% and 70.00 ± 14.49%, respectively) were significantly worse than those of the simple group (61.32 ± 5.40% and 91.90 ± 3.20%, P = 0.0468 and 0.0348, respectively).
Relapsed patients:
Five relapsed patients with additional/ complex chromosome anomalies (Nos 3, 5, 8, 10 and 24, Table 2 ) were compared to 39 patients with classical t(15;17) at relapse. These five patients had WBCs ranging from 0.6 × 10 9 /l to 9.1 × 10 9 /l (medium: 1.5 × 10 9 /l), and their ages ranged from 19 to 56 (medium: 49), without significant differences as compared to the control patients (0.8 × 10 9 /l to 9.5 × 10 9 /l (medium: 2.4 × 10 9 /l) and 24 to 59 (medium: 45), respectively). Three cases (3, 5 and 8) achieved second CR using As 2 O 3 or ATRA/chemotherapy, but died of another relapse. Two cases (10 and 24) failed to regain remission. They all died within 10 months after relapse, in contrast to the 1 year survival of 81.42 ± 6.96% in the control group.
Discussion
Although an overwhelming majority of APL cases are characterized by t (15;17) leading to the formation of PML-RAR␣ fusion gene, additional, complex and/or variant karyotypes have been reported in some cases. In this study on 284 APL patients, 26 displayed karyotypes other than simple t (15;17) . In case 10, only the PML-RAR␣ fusion on der(15), but not the reciprocal RAR␣-PML fusion, was found at relapse due to the complex variant translocation. Such cases have also been described by others. [30] [31] [32] [33] [34] [35] [36] These observations, together with the Leukemia fact that RAR␣-PML mRNA was only found in 70-80% patients, 8, 37 confirm that PML-RAR␣ is the critical event in APL leukemogenesis. In addition to complex translocations, many chromosome abnormalities involving a single chromosome or chromosomal region were identified, such as addition, duplication, insertion and inversion, demonstrating that complicated cytogenetic changes may also contribute to the primary pathogenesis and/or disease evolution in APL.
In our series, two variant translocations, t(5;17)(q35;q21) and t(11;17)(q23;q21), were identified. The leukemic promyelocytes in both cases exhibited some cytological features as those described in two carefully conducted recent studies on a group of similar patients, 38, 39 such as hypergranular cytoplasm, relatively regular nucleus and absence of Auer rods. In contrast to the case described by Corey et al, 16 our t(5;17) case showed positive RT-PCR only for NPM-RAR␣, but not for the reciprocal RAR␣-NPM transcript. Hence, our data support the idea that NPM-RAR␣, by analogy to PML-RAR␣, plays a crucial role in leukemogenesis. As for the response to treatment, former studies indicated that t(5;17) blasts were responsive to ATRA both in vitro and in vivo. 40, 41 However, it was impossible to evaluate the drug response in our t(5;17) patient, since he died within 5 days of ATRA therapy. Our t (11;17) case was the first one reported in the literature. 15, 24 Subsequent studies on a large group of t(11;17) cases, including this index patient, indicated that they were resistant to ATRA and chemotherapy. [42] [43] [44] The molecular understanding of this phenotype has been advanced when PLZF-RAR␣ fusion receptor is found to have tighter binding ability, as compared to PML-RAR␣, to nuclear receptor co-repressor complex, which displays histone deacetylase activity and maintains the chromatin structure of RA target genes in a repressed status. 45 Recently, the successful use of histone deacetylase inhibitor and ATRA in the differentiation induction of t(11;17) cells offered a new insight into the targeted transcription therapy. 46 A previous study described that some APL cases with additional chromosome abnormalities may have no Auer rods in leukemic promyelocytes and may be morphologically confused with other types of AML, in particular, AML-M2 and M5. 47 Combined use of cytochemical, cytogenetic and molecular assays should be helpful for definite diagnosis. In our study, we observed two patients with mixed M2/M3 morphology. In case 24, two morphological contingents (M3 and M2) were observed in BM at diagnosis, although PML-RAR␣ was the only molecular marker detected. CR was achieved with ATRA. Upon relapse, a distinct clone emerged with an increased percentage of myelocytes and appearance of t (8;21) as the only translocation revealed by cytogenetic and FISH analysis. Of note, both AML1-ETO and PML-RAR␣ transcripts were detectable, suggesting the presence of a minimal residual disease of APL in addition to the predominating t(8;21) cells. There could be two possible explanations for this situation. The first could be a clonal switch from leukemic stem cells which might give rise to both t(15;17)-and t(8;21)-bearing clones. The second could be that the clone which emerged at relapse represented a second leukemia, particularly because the patient was exposed to topoisomerase II inhibitor VP-16. 48 The situation in case 26 was quite different, since two leukemic populations could be identified by karyotype analysis, one with t(8;21) and the other with both t(8;21) and t (15;17) . On the other hand, cases 10 and 12 are worth noting in that both showed monocytic phenotype at diagnosis or relapse. Case 12 had a duplication of 11q and an atypical M3/M5 phenotype at diagnosis. Using FISH, a region containing MLL gene located at 11q23 was duplicated. This obser-Leukemia vation is interesting since MLL abnormalities are common in infant AML-M4 and M5, 49 although the biological consequence of this duplication is still uncertain. In case 10 with monocytic transformation during disease progression, there was a triple or quadruple amplification of MYC gene. MYC is known to be activated through amplification or overexpression in many solid tumors and leukemia. 50 However, the role this 8 q duplication may play in the morphologic transformation towards M5 needs further investigation.
The co-existence of t(15;17) with other specific translocation may provide useful information on the level of cells from which leukemias originate. In case 11, Ph chromosome was found simultaneously with t(15;17) by karyotyping, as confirmed by positive RT-PCR results for both BCR-ABL and PML-RAR␣ fusion transcripts. Since Ph chromosome is a marker of CML, this patient was suggested to have a CML blast crisis in the form of APL, with t(15;17) as a secondary leukemogenic event. 51 The appearance of a small contingent containing both t(8;21) and t(15;17) on the background of cells with only t(8;21) in case 26 is very interesting, and suggests the differentiation stage of t(8;21) leukemic clone could be higher than that of t (15;17) . Previous studies showed that t(15;17) could be found in acute eosinophilic leukemia 52 or leukemia with basophilic differentiation. 53 All this information may allow a hierarchy to be established for myeloid precursors giving rise to distinct leukemias: Ph(+) stem cells are situated at the highest level, and the progenitors in t(8;21) leukemia are higher than those in t(15;17). The t(15;17) progenitors could commit to neutrophilic, eosinophilic or basophilic differentiation pathways, generating leukemias with distinct phenotypes.
Finally, this study offers some data on the prognostic relevance of the additional and complex chromosomal aberrations. Of note, four APL patients presenting with structural chromosomal abnormalities other than t(15;17) and morphological ambiguity showed poor response to therapy, including resistance to ATRA (case 11), As 2 O 3 (cases 12 and 24) or chemotherapy (case 10). These chromosomal aberrations may thus render leukemic cells insensitive to drugs. On the other hand, our study suggests an unfavorable RFS and OS for patients with additional/complex karyotype, as compared to the patients with sole t(15;17). Moreover, there seemed to be a difference with regard to the survival between additional/complex karyotype group and the simple group among relapsed cases. These results are thus in line with a early report by Hiorns et al, 54 which indicated chromosomal aberrations in addition to t(15;17) as an important prognostic factor for outcome in APL patients. However, one previous report 10 and two large recent studies by the Spanish Pethema 55 and UK MRC 56 groups found no significant influence of additional abnormalities to t(15;17) in APL patients. One of the reasons for this discrepancy could be the intensity of the induction/consolidation/maintenance chemotherapy. In our group, we had a significant number of patients treated in the late 1980s and early 1990s when ATRA was used as the only drug for remission induction. It is possible that the prognostic significance of additional/complex cytogenetic abnormalities be revealed only when initial treatment is relatively weak, while remission induction with ATRA and high-dose chemotherapy, like that in the PETHEMA and MRC studies, attenuate or even eliminate its significance. Hence, the additional/complex karyotype may be of limited prognostic value and its impact may depend largely on the treatment protocols used.
